1
|
Viehweger F, Böcker C, Weidemann S, Freytag M, Menz A, Büscheck F, Luebke AM, Putri D, Kluth M, Hube-Magg C, Hinsch A, Lennartz M, Lutz F, Reiswich V, Höflmayer D, Fraune C, Möller K, Bernreuther C, Lebok P, Sauter G, Steurer S, Dum D, Marx AH, Simon R, Krech T, Clauditz TS, Jacobsen F, Gorbokon N, Burandt E, Minner S, Kind S. Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities. Diagn Pathol 2024; 19:12. [PMID: 38218896 PMCID: PMC10788021 DOI: 10.1186/s13000-023-01434-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Accepted: 12/21/2023] [Indexed: 01/15/2024] Open
Abstract
BACKGROUND Prostein (P501S), also termed solute carrier family 45 member 3 (SLC45A3) is an androgen regulated protein which is preferentially expressed in prostate epithelial cells. Because of its frequent expression in prostate cancer, prostein was suggested a diagnostic prostate cancer marker. METHODS In order to comprehensively assess the diagnostic utility of prostein immunohistochemistry, a tissue microarray containing 19,202 samples from 152 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. RESULTS Prostein immunostaining was typically cytoplasmic, granular and perinuclear. Prostein positivity was seen in 96.7% of 419 prostate cancers including 78.3% with strong staining. In 16,709 extra-prostatic tumors, prostein positivity was observed in 7.2% of all cases but only 0.3% had a strong staining. Overall, 50 different extra-prostatic tumor categories were prostein positive, 12 of which included at least one strongly positive case. Extra-prostatic tumors with highest rates of prostein positivity included different subtypes of salivary gland tumors (7.6-44.4%), neuroendocrine neoplasms (15.8-44.4%), adenocarcinomas of the gastrointestinal tract (7.3-14.8%), biliopancreatic adenocarcinomas (3.6-38.7%), hepatocellular carcinomas (8.1%), and adenocarcinomas of other organs (up to 21%). CONCLUSIONS Our data provide a comprehensive overview on prostein expression in human cancers. Prostein is a highly sensitive prostate cancer marker occurring in > 96% of prostate cancers. Because prostein can also be expressed in various other tumor entities, classifying of a tumor mass as a prostate cancer should not be based on prostein positivity alone.
Collapse
Affiliation(s)
- Florian Viehweger
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Carola Böcker
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Sören Weidemann
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Morton Freytag
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Anne Menz
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Franziska Büscheck
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Andreas M Luebke
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Devita Putri
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Martina Kluth
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Claudia Hube-Magg
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Andrea Hinsch
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Maximilian Lennartz
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Florian Lutz
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Viktor Reiswich
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Doris Höflmayer
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Christoph Fraune
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Katharina Möller
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Christian Bernreuther
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Patrick Lebok
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
- Institute of Pathology, Clinical Center Osnabrueck, Am Finkenhuegel 1, Osnabrueck, 49076, Germany
| | - Guido Sauter
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Stefan Steurer
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - David Dum
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Andreas H Marx
- Department of Pathology, Academic Hospital Fuerth, Jakob-Henle-Straße 1, Fuerth, 90766, Germany
| | - Ronald Simon
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
| | - Till Krech
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
- Institute of Pathology, Clinical Center Osnabrueck, Am Finkenhuegel 1, Osnabrueck, 49076, Germany
| | - Till S Clauditz
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Frank Jacobsen
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Natalia Gorbokon
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Eike Burandt
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Sarah Minner
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| | - Simon Kind
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
| |
Collapse
|
2
|
Chen J, Shi M, Chuen Choi SY, Wang Y, Lin D, Zeng H, Wang Y. Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta‐analysis. BJUI COMPASS 2023; 4:256-265. [PMID: 37025467 PMCID: PMC10071089 DOI: 10.1002/bco2.212] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 12/19/2022] [Indexed: 01/04/2023] Open
Abstract
Background Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. We performed a systematic review and meta-analysis to evaluate the prevalence of genomic alterations in NEPC and better understand its molecular features to potentially inform precision medicine. Methods EMBASE, PubMed, and Cochrane Central Register of Controlled Trials databases were searched for eligible studies until March 2022. Study qualities were assessed using the Q-genie tool. The prevalence of gene mutations and copy number alterations (CNAs) were extracted, and meta-analysis was performed using R Studio with meta package. Results A total of 14 studies with 449 NEPC patients were included in this meta-analysis. The most frequently mutated gene in NEPC was TP53 (49.8%), and the prevalence of deleterious mutations in ATM/BRCA was 16.8%. Common CNAs in NEPC included RB1 loss (58.3%), TP53 loss (42.8%), PTEN loss (37.0%), AURKA amplification (28.2%), and MYCN amplification (22.9%). RB1/TP53 alterations and concurrent RB1 and TP53 alterations were remarkably common in NEPC, with a prevalence of 83.8% and 43.9%, respectively. Comparative analyses indicated that the prevalence of (concurrent) RB1/TP53 alterations was significantly higher in de novo NEPC than in treatment-emergent NEPC (t-NEPC). Conclusions This study presents the comprehensive prevalence of common genomic alterations and potentially actionable targets in NEPC and reveals the genomic differences between de novo NEPC and t-NEPC. Our findings highlight the importance of genomic testing in patients for precision medicine and provide insights into future studies exploring different NEPC subtypes.
Collapse
Affiliation(s)
- Junru Chen
- Department of Urology, Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan China
- Vancouver Prostate Centre Vancouver BC Canada
- Department of Urologic Sciences, Faculty of Medicine University of British Columbia Vancouver BC Canada
- Department of Experimental Therapeutics BC Cancer Agency Vancouver BC Canada
| | - Mingchen Shi
- Vancouver Prostate Centre Vancouver BC Canada
- Department of Urologic Sciences, Faculty of Medicine University of British Columbia Vancouver BC Canada
- Department of Experimental Therapeutics BC Cancer Agency Vancouver BC Canada
| | - Stephen Yiu Chuen Choi
- Vancouver Prostate Centre Vancouver BC Canada
- Department of Urologic Sciences, Faculty of Medicine University of British Columbia Vancouver BC Canada
- Department of Experimental Therapeutics BC Cancer Agency Vancouver BC Canada
| | - Yu Wang
- Vancouver Prostate Centre Vancouver BC Canada
- Department of Urologic Sciences, Faculty of Medicine University of British Columbia Vancouver BC Canada
- Department of Experimental Therapeutics BC Cancer Agency Vancouver BC Canada
| | - Dong Lin
- Vancouver Prostate Centre Vancouver BC Canada
- Department of Urologic Sciences, Faculty of Medicine University of British Columbia Vancouver BC Canada
- Department of Experimental Therapeutics BC Cancer Agency Vancouver BC Canada
| | - Hao Zeng
- Department of Urology, Institute of Urology, West China Hospital Sichuan University Chengdu Sichuan China
| | - Yuzhuo Wang
- Vancouver Prostate Centre Vancouver BC Canada
- Department of Urologic Sciences, Faculty of Medicine University of British Columbia Vancouver BC Canada
- Department of Experimental Therapeutics BC Cancer Agency Vancouver BC Canada
| |
Collapse
|
3
|
Lombardo R, Rovesti L, Cicione A, Gravina C, Franco A, Stira J, Simone G, D'Annunzio S, Nacchia A, Papalia R, Mastroianni R, Collura D, Brassetti A, Vecchione A, Muto G, Gallucci M, Tubaro A, De Nunzio C. Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort. Prostate 2022; 82:1400-1405. [PMID: 35923120 DOI: 10.1002/pros.24412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 05/31/2022] [Accepted: 06/20/2022] [Indexed: 11/10/2022]
Abstract
BACKGROUND Recently a possible link between elevated Chromogranin A (CgA) levels and poorly differentiated prostate cancer has been proposed. The aim of our study was to explore the association of CgA levels and the risk of poorly differentiated prostate cancer (PCa) in men undergoing radical retropubic prostatectomy (RRP). MATERIALS AND METHODS From 2012 onwards, 335 consecutive men undergoing RRP for PCa at three centers in Italy were enrolled into a prospective database. Body mass index (BMI) was calculated before RRP. Blood samples were collected and tested for total prostate-specific antigen (PSA) levels and chromogranin A (CgA). We evaluated the association between serum levels of CgA and upstaging and upgrading using logistic regression analyses. RESULTS Median age and preoperative PSA levels were 65 years (interquartile range [IQR]: 60-69) and 7.2 ng/ml (IQR: 5.3-10.4), respectively. Median BMI was 26.1 kg/m2 (IQR: 24-29) with 56 (16%) obese (BMI ≥ 30 kg/m2 ). Median CgA levels were 51 (39/71). Overall, 129/335 (38,5%) presented an upstaging, and 99/335 (30%) presented an upgrading. CgA was not a predictor of upstaging or upgrading on RP. CONCLUSIONS In our multicenter cohort of patients, CgA is not a predictor of poorly differentiated PCa on radical prostatectomy. According to our experience, CgA should not be considered a reliable marker to predict poorly differentiated or advanced prostate cancer.
Collapse
Affiliation(s)
- Riccardo Lombardo
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Lorenzo Rovesti
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Antonio Cicione
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Carmen Gravina
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Antonio Franco
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Jordi Stira
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Giuseppe Simone
- Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy
| | - Simone D'Annunzio
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Antonio Nacchia
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Rocco Papalia
- Department of Urology, "Campus Bio-Medico" University, Rome, Italy
| | | | - Devis Collura
- Department of Urology, "San Giovanni Bosco" Hospital, Turin, Italy
| | - Aldo Brassetti
- Department of Urology, "Regina Elena" National Cancer Institute, Rome, Italy
| | - Andrea Vecchione
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Giovanni Muto
- Department of Urology, "Campus Bio-Medico" University, Rome, Italy
| | - Michele Gallucci
- Department of Urology, "Campus Bio-Medico" University, Rome, Italy
| | - Andrea Tubaro
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| | - Cosimo De Nunzio
- Department of Urology, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy
| |
Collapse
|